Antimicrobials in the management of inflammatory bowel disease.
Many experimental and clinical observations suggest a potential role for intestinal microflora in the pathogenesis of inflammatory bowel disease (IBD). Manipulation of the luminal content using antibiotics may therefore represent a potentially effective therapeutic option. However, the available studies do not support the use of antimicrobials in ulcerative colitis and larger studies are required. These drugs are however effective in treating septic complications of Crohn's disease (CD). The use of antibacterial agents as primary therapy for CD is more controversial, although this approach is frequently and successfully adopted in clinical practice. Despite the fact that properly controlled trials have been not carried out, antimicrobials are the mainstay of the treatment of pouchitis. Rifaximin is a poorly absorbed, broad-spectrum antibiotic that, thanks to its efficacy and long-term safety, could represent the preferred tool of manipulating enteric flora in patients with IBD. Preliminary data suggest that rifaximin may be beneficial in the treatment of active ulcerative colitis (and pouchitis), mild to moderate CD as well as prevention of post-operative recurrence of CD.
Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy. paolo@med.unibo.it
Paolo
P
Gionchetti
Fernando
F
Rizzello
Karen M
KM
Lammers
Claudia
C
Morselli
Rosy
R
Tambasco
Massimo
M
Campieri
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
D000890:Anti-Infective Agents